CSIMarket Company Name, Ticker, Customers, else..
 
Io Biotech Inc   (NASDAQ: IOBT)
Other Ticker:  
 
 
Price: $0.9450 $0.05 5.575%
Day's High: $0.99 Week Perf: 12.96 %
Day's Low: $ 0.87 30 Day Perf: 22.57 %
Volume (M): 231 52 Wk High: $ 1.89
Volume (M$): $ 218 52 Wk Avg: $1.28
Open: $0.90 52 Wk Low: $0.66



 Market Capitalization (Millions $) 62
 Shares Outstanding (Millions) 66
 Employees 26
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -90
 Cash Flow (TTM) (Millions $) -86
 Capital Exp. (TTM) (Millions $) 0

Io Biotech Inc
Io Biotech Inc is a biotechnology company that focuses on the development of immunotherapies for the treatment of cancer and other diseases. They aim to revolutionize the field of immunotherapy by harnessing the power of the immune system to target and eliminate cancer cells. Io Biotech Inc utilizes cutting-edge technology and innovative strategies to create personalized immunotherapeutic solutions tailored to the individual needs of patients. Through their research and development efforts, they strive to improve patient outcomes and make significant advancements in the field of cancer treatment.


   Company Address: Ole Maal?es Vej 3 Copenhagen N 0
   Company Phone Number: 7070 2980   Stock Exchange / Ticker: NASDAQ IOBT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
MEIP      % 
NRIX      % 
RYTM      % 
SDGR      % 
SUPN      % 
YMAB      % 
• View Complete Report
   



Product Service News

Promising Outcomes in Metastatic Lung Cancer IO Biotechs Innovative Vaccine and Keytruda Show Enhanced Efficacy in P...

Published Thu, Nov 7 2024 3:00 PM UTC

In a groundbreaking development for the treatment of metastatic non-small cell lung cancer (NSCLC), IO Biotech has reported positive results from its Phase 2 IOB-022 study, evaluating the efficacy and safety of its off-the-shelf therapeutic cancer vaccine, IO102-IO103, in combination with the well-established immunotherapy agent, Keytruda (pembrolizumab). This innovative the...
Product Service News

Advancements in Immunotherapy Promising Phase 2 Results of IO102-IO103 for First-Line Treatment of Advanced Head and ...

Published Sat, Sep 14 2024 6:30 AM UTC

The field of oncology has seen remarkable advancements over the past decade, particularly in the domain of immunotherapy. One area of significant interest is advanced head and neck cancer (HNC), which often presents a complex challenge due to its unique biological characteristics and the surrounding critical structures. A recent Phase 2 clinical trial conducted by IO Biotec...
Clinical Study

An Apotheosis of Therapeutic Innovation Update on the Pivotal Phase 3 Trial of IO102-IO103 in Conjunction with Pem...

Published Fri, Aug 30 2024 8:05 PM UTC

In an epoch characterized by unprecedented advancements in the field of medicine, the emergence of novel therapeutic modalities inspires both hope and rigorous scrutiny among the discerning scholar-practitioners dedicated to the ennoblement of human health. It is, therefore, with great anticipation that we present to the esteemed readership of CSIMarket.com the most recent...
Clinical Study

IO Biotechs Groundbreaking Cancer Vaccine Data Accepted for ESMO Congress 2024 A New Hope for Head and Neck Ca...

Published Thu, Jul 25 2024 8:05 PM UTC

New York, July 25, 2024 In a significant advancement for cancer treatment, IO Biotech (Nasdaq: IOBT), a pioneering clinical-stage biopharmaceutical company, has announced that new data from its innovative head and neck cancer trial has been accepted for presentation at the prestigious European Society for Medical Oncology (ESMO) Congress 2024. This announcement highlights...
Clinical Study

IO Biotech Set to Present Revolutionary Therapeutic Cancer Vaccine Findings at 2024 ASCO Annual Meeting

Published Wed, Apr 24 2024 8:30 PM UTC

The accepted abstract details the ongoing research on the IO102-IO103 vaccine candidate, a cornerstone in the company s pipeline. The IO102-IO103 is considered a groundbreaking approach in cancer therapeutics. It leverages the immune system s inherent mechanisms, allowing a person s own physiological processes to combat malignant cells.Specific endorsement for this groundbre...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com